Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The second patient had stage III BRAF V600R mutant melanoma that was treated with pembrolizumab and dabrafenib, and also developed a regressed melanocytic nevus.
|
29152725 |
2019 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In contrast, mutation analyses performed in parallel in melanocytic nevi of the eyelid identified BRAF V600E alterations in all 3 cases.
|
29406329 |
2019 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The melanoma transformation rate of an individual nevus is very low despite the detection of oncogenic BRAF or NRAS mutations in 100% of nevi.
|
29476775 |
2018 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
They were ulcerated (p = 0.0001), they were associated with neurotropism (p = 0.0001), they lacked the BRAF mutation (p = 0.03), and they less often coexisted with a preceding melanocytic nevus (p = 0.0001).
|
29860247 |
2018 |
Melanocytic nevus
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRAF mutations were present in 92% (n = 12/13) of globular and 100% (n = 12/12) of PG naevi, whereas reticular naevi were 67% (n = 10/15) BRAF- and 33% (n = 5/15) NRAS-mutant (P = 0·037).
|
28714107 |
2018 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
|
29653212 |
2018 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings document that common conjunctival melanocytic nevi have mutually exclusive mutations in BRAF and NRAS.
|
29332123 |
2018 |
Melanocytic nevus
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Both drug resistance and inherent transition from melanocytic nevi to malignant melanoma involve the overexpression of histone deacetylases (HDACs) and a B-Raf proto-oncogene (BRAF) mutation.
|
30194076 |
2018 |
Melanocytic nevus
|
0.500 |
Biomarker
|
disease |
BEFREE |
On histopathologic analysis, the lesion was determined to be BRAF-negative invasive melanoma arising in association with melanocytic nevus.
|
29126970 |
2017 |
Melanocytic nevus
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population.
|
29507566 |
2017 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
RhoJ deletion in BRAF mutant melanocytes modulates the expression of the pro-apoptotic protein BAD as well as genes involved in cellular metabolism, impairing nevus formation, cellular transformation, and metastasis.
|
28753606 |
2017 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the β-catenin pathway change the phenotype of a common nevus with BRAF mutation into that of DPN, with increased pigmentation, cell volume and nuclear cyclin D1 levels.
|
28935960 |
2017 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations were more frequent in males, in young patients, and in tumours with a sun-exposed tumour location (bulbar conjunctiva or caruncle), with a mixed or non-pigmented colour, with absence of primary acquired melanosis, and with origin in a nevus.
|
27192168 |
2016 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This effect of the BRAF(V) (600E) mutation on the growth rate was not observed in melanocytic naevi (mean 1·01 vs. 0·47 mm(2) /year, P = 0·274).
|
26613644 |
2016 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations were associated with T1 stage (p = 0.007), young age (p = 0.001), male gender (p = 0.02), sun-exposed location (p = 0.01), mixed/non-pigmented tumour colour (p = 0.02) and nevus origin (p = 0.005), but did not associate with prognosis.
|
27009410 |
2016 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Acquired melanocytic nevi harbor oncogenic mutations in BRAF, which is the predominant oncogene associated with melanoma.
|
26300491 |
2015 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Immunohistochemistry showed that the naevus cells lacked a BRAF V600E mutation.
|
25380183 |
2015 |
Melanocytic nevus
|
0.500 |
Biomarker
|
disease |
BEFREE |
Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.
|
26190239 |
2015 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the present study, the frequency of BRAF V600E mutation was evaluated in Russian patients with melanocytic lesions, of which 41.25% were primary melanoma and 60% were melanocytic nevi.
|
25888143 |
2015 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A prime example is mutant BRAF, which drives OIS in melanocytic nevi.
|
24703243 |
2014 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In contrast, only 21% of the primary melanomas unassociated with naevi were BRAF(V600E) mutant (p = 0.009).Our results suggest that melanomas with associated naevi have a higher frequency of BRAF(V600E) mutations than melanomas unassociated with naevi.
|
24614711 |
2014 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The presence of either a predominantly dermal growth pattern or large junctional nests was found in 13 of 15 naevi positive for BRAF V600E and in two of 10 naevi negative for BRAF V600E (86·7% vs. 20%, P = 0·002).
|
25039578 |
2014 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We also characterize the frequency of BRAF mutations in female genital tract melanomas compared with melanocytic nevi.
|
24842760 |
2014 |
Melanocytic nevus
|
0.500 |
Biomarker
|
disease |
BEFREE |
Biopsy findings from 1 unchanged and 1 involuted nevus showed BRAF wild type in the unchanged nevus, BRAFV600E mutation in the involuting nevus, and no malignant histopathologic characteristics in either one.
|
24695877 |
2014 |
Melanocytic nevus
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The BRAF-V600E status of confirmed new primary melanoma and dysplastic naevi was tested using a genetic mutation assay and immunohistochemistry.
|
24531394 |
2014 |